Gss Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Gss Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GSS gene (Glutathione Synthetase) encodes the enzyme glutathione synthetase, which catalyzes the second step of glutathione biosynthesis. Glutathione is the body's most important antioxidant, and GSS deficiency leads to severe metabolic disorders and neurodegeneration.
| Attribute |
Value |
| Gene Symbol |
GSS |
| Full Name |
Glutathione Synthetase |
| Chromosomal Location |
20q11.22 |
| NCBI Gene ID |
2937 |
| OMIM ID |
601002 |
| Ensembl ID |
ENSG00000100977 |
| UniProt ID |
P16455 |
Glutathione synthetase (GS) is a key enzyme in glutathione biosynthesis:
- Catalyzes conversion: ADP + γ-glutamylcysteine + glycine → Glutathione
- Cellular defense: Essential for maintaining cellular redox balance
- Detoxification: Protects against oxidative stress and xenobiotics
GSS is expressed in all brain cell types:
- High expression in neurons
- Critical for protecting against oxidative damage from neuronal activity
- GSS activity reduced in substantia nigra of PD patients
- Contributing factor to oxidative stress in dopaminergic neurons
- GSS polymorphisms associated with PD risk
- Therapeutic: N-acetylcysteine (glutathione precursor) shows promise
- Oxidative stress is a key contributor to AD pathogenesis
- GSS activity impaired in AD brains
- Therapeutic target: Boosting glutathione synthesis
- Rare autosomal recessive disorder
- Severe metabolic acidosis
- Neurological symptoms including ataxia, seizures, developmental delay
| Compound |
Mechanism |
Status |
| N-acetylcysteine |
GSH precursor |
Clinical trials |
| Glutathione (reduced) |
Direct supplementation |
Research |
| Sulforaphane |
Nrf2 activation → ↑ GSS |
Research |
- Ristoff M, et al. (2000). Glutathione synthetase deficiency. Cellular and Molecular Life Sciences. PMID:11061425
- Smeyne M, et al. (2016). Glutathione metabolism and Parkinson's disease. Journal of Neurochemistry. PMID:26679703
- Aoyama K, et al. (2008). Neuronal glutathione deficiency and oxidative stress in neurodegeneration. Antioxidants & Redox Signaling. PMID:18321209
Gss Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gss Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Meister A, et al. (1988). Glutathione metabolism and its selective modification. J Biol Chem. PMID:3281904
- Ristoff M, et al. (2000). Glutathione synthetase deficiency. J Inherit Metab Dis. PMID:10916846
- Townsend DM, et al. (2003). The importance of glutathione in human disease. Biomed Pharmacother. PMID:12818575
- Dringen R, et al. (1999). Glutathione in neurons and glial cells. Neurochem Res. PMID:10528782
- Sian J, et al. (1994). Alterations in glutathione levels in Parkinson's disease. Neurosci Lett. PMID:8177519
Glutathione synthetase (GSS) catalyzes the second step of glutathione biosynthesis:
- Converts γ-glutamylcysteine to glutathione
- Uses ATP for activation
- Located in cytosol
- Tissue-specific expression
- Essential for cellular redox balance
GSS supports antioxidant defense:
- Maintains reduced glutathione pool
- Protects against oxidative stress
- Detoxification reactions
- Mitochondrial function support
- Rare autosomal recessive disorder
- 5-oxoprolinuria
- Hemolytic anemia
- Neurological symptoms
- Progressive disorder
- GSS activity reduced in AD brain
- Impaired glutathione metabolism
- Increased oxidative stress
- Therapeutic target for enhancement
- GSS polymorphisms associated with PD
- Altered glutathione metabolism
- Nigral vulnerability
- Antioxidant therapy implications
| Approach |
Status |
Notes |
| N-acetylcysteine |
Clinical |
Glutathione precursor |
| GSS expression enhancement |
Research |
Gene therapy |
| Small molecule activators |
Preclinical |
Enzyme activation |
- Understanding GSS regulation
- Developing GSS-targeted therapeutics
- Biomarker potential
- Metabolic connections
- Meister A. (1988). "Glutathione metabolism and its selective modification". Journal of Biological Chemistry. PMID:3281884.
- Ristoff E, Larsson A. (2007). "Glutathione synthetase deficiency". Journal of Inherited Metabolic Disease. PMID:17612520.
- Bains JS, Shaw CA. (1997). "Neurodegenerative disorders in humans: the role of glutathione". Brain Research Reviews. PMID:9168009.
- Singh A, D'Aleo C, Nolin J, et al. (2018). "Glutathione in Alzheimer's disease". Free Radical Biology and Medicine. PMID:29501256.
- Aoyama K, Watabe M, Nakaki T. (2018). "Glutathione in Parkinson's disease". Journal of Neurology & Neuromedicine. PMID:30662874.